XORTX Therapeutics Secures Orphan Drug Designation for Oxypurinol to Treat Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company that aims to create new therapies to treat progressive kidney disease, is excited to announce that they have received Orphan Drug ...
XORTX Therapeutics Submits Orphan Drug Designation Request for XRx-008 Program to FDA for ADPKD Treatment
XORTX Therapeutics Inc., a late-stage clinical pharma company focused on developing novel therapies to treat progressive kidney disease, has submitted an Orphan Drug Designation request to the U.S. Fo ...